Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertension

Arthritis and Rheumatism

Volumn 65, Issue 11, 2013, Pages 2928-2939

  Derrett Smith, Emma C ^a   Dooley, Audrey ^a   Gilbane, Adrian J ^a   Trinder, Sarah L ^a   Khan, Korsa ^a   Baliga, Reshma ^b   Holmes, Alan M ^a   Hobbs, Adrian J ^b   Abraham, David ^a   Denton, Christopher P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; KI 67 ANTIGEN; SEMAXANIB; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY MEDIA; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOPULMONARY HEMODYNAMICS; CELL PROLIFERATION; CHRONIC INFLAMMATION; CLINICAL FEATURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; EXPERIMENTAL MODEL; EXPLANT; FIBROSIS; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HYPOXIA; IN VIVO STUDY; INFLAMMATORY INFILTRATE; LUNG BLOOD VESSEL; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; SCLERODERMA; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SYSTEMIC SCLEROSIS; TRANSGENIC MOUSE; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; HYPERTENSION, PULMONARY; INDOLES; LAC OPERON; MALE; MICE; MICE, TRANSGENIC; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; PULMONARY CIRCULATION; PYRROLES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84886801549     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38078     Document Type: Article

References (33)

1. Hachulla E, Coghlan JG,. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism [review]. Ann Rheum Dis 2004; 63: 1009-14.
2. Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and meta-analysis of 5 studies. J Rheumatol 2010; 37: 2290-8.
3. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043-50.
4. Tan FK,. Systemic sclerosis: the susceptible host (genetics and environment) [review]. Rheum Dis Clin North Am 2003; 29: 211-37.
5. Jonigk D, Golpon H, Bockmeyer CL, Maegel L, Hoeper MM, Gottlieb J, et al. Plexiform lesions in pulmonary arterial hypertension: composition, architecture, and microenvironment. Am J Pathol 2011; 179: 167-79.
6. Al Sabbagh MR, Steen VD, Zee BC, Nalesnik M, Trostle DC, Bedetti CD, et al. Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol 1989; 16: 1038-42.
7. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, et al. Inflammation, growth factors and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54: S10-9.
8. Okawa-Takatsuji M, Aotsuka S, Fujinami M, Uwatoko S, Kinoshita M, Sumiya M,. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol 1999; 116: 174-80.
9. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM,. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998; 101: 927-34.
10. Choi JJ, Min DJ, Cho ML, Min SY, Kim SJ, Lee SS, et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003; 30: 1529-33.
11. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002; 4: R11.
12. Dorfmuller P, Humbert M, Perros F, Sanchez O, Simonneau G, Muller KM, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007; 38: 893-902.
13. Overbeek MJ, Vonk MC, Boonstra A, Voskuyl AE, Vonk-Noordegraaf A, Smit EF, et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 2009; 34: 371-9.
14. Tew MB, Arnett FC, Reveille JD, Tan FK,. Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases [letter]. Arthritis Rheum 2002; 46: 2829-30.
15. Wipff J, Kahan A, Hachulla E, Sibilia J, Cabane J, Meyer O, et al. Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 2007; 46: 622-5.
16. Wipff J, Dieude P, Guedj M, Ruiz B, Riemekasten G, Cracowski JL, et al. Association of a KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. Arthritis Rheum 2010; 62: 3093-100.
17. Denton CP, Zheng B, Evans LA, Shi-wen X, Ong VH, Fisher I, et al. Fibroblast-specific expression of a kinase-deficient type II transforming growth factor β receptor leads to paradoxical activation of TGF β signaling pathways with fibrosis in transgenic mice. J Biol Chem 2003; 278: 25109-19.
18. Denton CP, Lindahl GE, Khan K, Shiwen X, Ong VH, Gaspar NJ, et al. Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor-β receptor (TβRIIΔk). J Biol Chem 2005; 280: 16053-65.
19. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, McMahon G, Waltenberger J, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001; 15: 427-38.
20. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, et al. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2011; 184: 1171-82.
21. Hoyles RK, Khan K, Shiwen X, Howat SL, Lindahl GE, Leoni P, et al. Fibroblast-specific perturbation of transforming growth factor β signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. Arthritis Rheum 2008; 58: 1175-88.
22. Derrett-Smith EC, Dooley A, Khan K, Shi-wen X, Abraham D, Denton CP,. Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma. Arthritis Res Ther 2010; 12: R69.
23. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 2002; 3: 1-11.
24. Tanabe K, Tokuda H, Takai S, Matsushima-Nishiwaki R, Hanai Y, Hirade K, et al. Modulation by the steroid/thyroid hormone superfamily of TGF-β-stimulated VEGF release from vascular smooth muscle cells. J Cell Biochem 2006; 99: 187-95.
25. Mata-Greenwood E, Grobe A, Kumar S, Noskina Y, Black SM,. Cyclic stretch increases VEGF expression in pulmonary arterial smooth muscle cells via TGF-β1 and reactive oxygen species: a requirement for NAD(P)H oxidase. Am J Physiol Lung Cell Mol Physiol 2005; 289: L288-98.
26. Kobayashi T, Liu X, Wen FQ, Fang Q, Abe S, Wang XQ, et al. Smad3 mediates TGF-β1 induction of VEGF production in lung fibroblasts. Biochem Biophys Res Commun 2005; 327: 393-8.
27. Ferrari G, Terushkin V, Wolff MJ, Zhang X, Valacca C, Poggio P, et al. TGF-β1 induces endothelial cell apoptosis by shifting VEGF activation of p38MAPK from the prosurvival p38β to proapoptotic p38α. Mol Cancer Res 2012; 10: 605-14.
28. Fernandes F, Ramires FJ, Arteaga E, Ianni BM, Bonfa ES, Mady C,. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail 2003; 9: 311-7.
29. Overbeek MJ, Lankhaar JW, Westerhof N, Voskuyl AE, Boonstra A, Bronzwaer JG, et al. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur Respir J 2008; 31: 1160-6.
30. Grigoryev DN, Mathai SC, Fisher MR, Girgis RE, Zaiman AL, Housten-Harris T, et al. Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res 2008; 151: 197-207.
31. Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 897-90.
32. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276: 38121-38.
33. Maurer B, Reich N, Juengel A, Kriegsmann J, Gay RE, Schett G, et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 2012; 71: 1382-7.